Biogenity ApS: Financial statements 2020
CVR: 39606925
Source: annual report 2020, Danish Business Authority
01/07/2019 – 30/06/2020
Biogenity ApS (CVR 39606925) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -115,272 and a net result of DKK 71,526 compared with DKK 141,285 the year before. Equity in the 2020 report amounted to DKK 132,816. The solvency ratio was 41.1%.
- Gross Profit
- DKK -115,272
- Profit/Loss
- DKK 71,526
- Equity
- DKK 132,816
- Total Assets
- DKK 322,849
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -115 t. | 72 t. | 133 t. | - |
| 2019 | - | -71 t. | 141 t. | 141 t. | - |
Official annual report
How creditworthy is Biogenity ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreAbout Biogenity ApS
Biogenity ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kenneth Kastaniegaard and Louis Loeb. The board consists of Louis Loeb (chair) and Kenneth Kastaniegaard. The company is owned by L.Loeb Holding ApS and Kastaniegaard Holding ApS. According to the 2025 annual report, the company had an average of 4 employees. In 2025, the company reported a gross profit of DKK 1,387,873 and a net result of DKK -453,753 compared with DKK -342,877 the year before. Equity in the 2025 report amounted to DKK -189,867.